Literature DB >> 16923606

Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement.

M Dominici1, K Le Blanc, I Mueller, I Slaper-Cortenbach, Fc Marini, Ds Krause, Rj Deans, A Keating, Dj Prockop, Em Horwitz.   

Abstract

The considerable therapeutic potential of human multipotent mesenchymal stromal cells (MSC) has generated markedly increasing interest in a wide variety of biomedical disciplines. However, investigators report studies of MSC using different methods of isolation and expansion, and different approaches to characterizing the cells. Thus it is increasingly difficult to compare and contrast study outcomes, which hinders progress in the field. To begin to address this issue, the Mesenchymal and Tissue Stem Cell Committee of the International Society for Cellular Therapy proposes minimal criteria to define human MSC. First, MSC must be plastic-adherent when maintained in standard culture conditions. Second, MSC must express CD105, CD73 and CD90, and lack expression of CD45, CD34, CD14 or CD11b, CD79alpha or CD19 and HLA-DR surface molecules. Third, MSC must differentiate to osteoblasts, adipocytes and chondroblasts in vitro. While these criteria will probably require modification as new knowledge unfolds, we believe this minimal set of standard criteria will foster a more uniform characterization of MSC and facilitate the exchange of data among investigators.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16923606     DOI: 10.1080/14653240600855905

Source DB:  PubMed          Journal:  Cytotherapy        ISSN: 1465-3249            Impact factor:   5.414


  2000 in total

1.  Direct modulation of the bone marrow mesenchymal stromal cell compartment by azacitidine enhances healthy hematopoiesis.

Authors:  Catharina Wenk; Anne-Kathrin Garz; Sonja Grath; Christina Huberle; Denis Witham; Marie Weickert; Roberto Malinverni; Julia Niggemeyer; Michèle Kyncl; Judith Hecker; Charlotta Pagel; Christopher B Mulholland; Catharina Müller-Thomas; Heinrich Leonhardt; Florian Bassermann; Robert A J Oostendorp; Klaus H Metzeler; Marcus Buschbeck; Katharina S Götze
Journal:  Blood Adv       Date:  2018-12-11

2.  Cellular behaviours of bone marrow-derived mesenchymal stem cells towards pristine graphene oxide nanosheets.

Authors:  Changbo Wei; Zifeng Liu; Fangfang Jiang; Binghui Zeng; Mingdi Huang; Dongsheng Yu
Journal:  Cell Prolif       Date:  2017-08-03       Impact factor: 6.831

Review 3.  Therapeutic potential of mesenchymal stem cells for severe acute lung injury.

Authors:  Michael A Matthay; B Taylor Thompson; Elizabeth J Read; David H McKenna; Kathleen D Liu; Carolyn S Calfee; Jae Woo Lee
Journal:  Chest       Date:  2010-10       Impact factor: 9.410

4.  Placental perivascular cells for human muscle regeneration.

Authors:  Tea Soon Park; Manuela Gavina; Chien-Wen Chen; Bin Sun; Pang-Ning Teng; Johnny Huard; Bridget M Deasy; Ludovic Zimmerlin; Bruno Péault
Journal:  Stem Cells Dev       Date:  2010-11-30       Impact factor: 3.272

5.  Gene Therapy for Bone Repair Using Human Cells: Superior Osteogenic Potential of Bone Morphogenetic Protein 2-Transduced Mesenchymal Stem Cells Derived from Adipose Tissue Compared to Bone Marrow.

Authors:  Sofia Bougioukli; Osamu Sugiyama; William Pannell; Brandon Ortega; Matthew H Tan; Amy H Tang; Robert Yoho; Daniel A Oakes; Jay R Lieberman
Journal:  Hum Gene Ther       Date:  2018-03-14       Impact factor: 5.695

Review 6.  Mesenchymal Stem/Progenitor Cells Derived from Articular Cartilage, Synovial Membrane and Synovial Fluid for Cartilage Regeneration: Current Status and Future Perspectives.

Authors:  Yi-Zhou Huang; Hui-Qi Xie; Antonietta Silini; Ornella Parolini; Yi Zhang; Li Deng; Yong-Can Huang
Journal:  Stem Cell Rev Rep       Date:  2017-10       Impact factor: 5.739

7.  Cytocompatibility evaluation of different biodegradable magnesium alloys with human mesenchymal stem cells.

Authors:  J Niederlaender; M Walter; S Krajewski; E Schweizer; M Post; Ch Schille; J Geis-Gerstorfer; Hans Peter Wendel
Journal:  J Mater Sci Mater Med       Date:  2013-12-11       Impact factor: 3.896

8.  Induced pluripotent mesenchymal stromal cell clones retain donor-derived differences in DNA methylation profiles.

Authors:  Kaifeng Shao; Carmen Koch; Manoj K Gupta; Qiong Lin; Michael Lenz; Stephanie Laufs; Bernd Denecke; Manfred Schmidt; Matthias Linke; Hans C Hennies; Jürgen Hescheler; Martin Zenke; Ulrich Zechner; Tomo Šarić; Wolfgang Wagner
Journal:  Mol Ther       Date:  2012-10-02       Impact factor: 11.454

9.  Materials-Directed Differentiation of Mesenchymal Stem Cells for Tissue Engineering and Regeneration.

Authors:  J Kent Leach; Jacklyn Whitehead
Journal:  ACS Biomater Sci Eng       Date:  2017-03-14

10.  Donor mesenchymal stromal cells (MSCs) undergo variable cardiac reprogramming in vivo and predominantly co-express cardiac and stromal determinants after experimental acute myocardial infarction.

Authors:  Gustavo Yannarelli; James N Tsoporis; Jean-Francois Desjardins; Xing Hua Wang; Ali Pourdjabbar; Sowmya Viswanathan; Thomas G Parker; Armand Keating
Journal:  Stem Cell Rev Rep       Date:  2014-04       Impact factor: 5.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.